GLPGF Stock - Galapagos N.V.
Unlock GoAI Insights for GLPGF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $275.65M | $239.72M | $505.28M | $484.85M | $478.05M |
| Gross Profit | $240.79M | $203.74M | $493.20M | $483.22M | $-45,614,000 |
| Gross Margin | 87.4% | 85.0% | 97.6% | 99.7% | -9.5% |
| Operating Income | $-188,338,000 | $-88,263,000 | $-267,520,000 | $-165,597,000 | $-178,632,000 |
| Net Income | $74.08M | $211.70M | $-217,991,000 | $-125,422,000 | $-311,001,000 |
| Net Margin | 26.9% | 88.3% | -43.1% | -25.9% | -65.1% |
| EPS | $1.12 | $3.21 | $-3.32 | $-1.91 | $-4.78 |
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Visit WebsiteEarnings History & Surprises
GLPGFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 23, 2026 | — | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.48 | $-3.59 | -646.8% | ✗ MISS |
Q3 2025 | Jul 23, 2025 | $-0.23 | $-1.89 | -705.5% | ✗ MISS |
Q2 2025 | Apr 23, 2025 | $-0.15 | $-2.55 | -1637.9% | ✗ MISS |
Q1 2025 | Feb 12, 2025 | $-0.53 | $0.40 | +175.0% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.17 | $-0.85 | -394.4% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.07 | $0.15 | +299.9% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.08 | $1.47 | +1853.3% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-2.18 | $2.62 | +220.2% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | $-1.09 | $0.41 | +137.9% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.81 | $0.08 | +110.4% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.97 | $0.38 | +139.5% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.53 | $-3.16 | -496.2% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.80 | $0.33 | +141.3% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.82 | $-0.29 | +64.6% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-1.06 | $-0.20 | +81.1% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.64 | $0.25 | +139.1% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-1.31 | $-0.99 | +24.4% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.87 | $-0.98 | -12.6% | ✗ MISS |
Q2 2021 | May 6, 2021 | $-0.55 | $0.14 | +125.5% | ✓ BEAT |
Latest News
Frequently Asked Questions about GLPGF
What is GLPGF's current stock price?
What is the analyst price target for GLPGF?
What sector is Galapagos N.V. in?
What is GLPGF's market cap?
Does GLPGF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GLPGF for comparison